Study Participants Elevated Level of the Natriuretic Peptide Among Adult Population in Regions Participating in the ESSE-RF Study and Its Association With Cardiovascular Diseases and Risk Factors

Aim: to study associations between elevated blood plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP), risk factors and cardiovascular diseases (CVD) in samples of adult population of Russian Federation (RF) aged 25-64 years. Materials and Methods. We analyzed data of examination of representative samples of population of 5 regions of RF obtained within the framework of the multicenter ESSE-RF study (2012-2013). Number of examined subjects was 8 077 (3 176 men). Methods included use of standard questionnaire, measurements of height, body mass, blood pressure (BP), and plasma NT-proBNP level. The following CVD were included into analysis: arterial hypertension (AH), ischemic heart disease (IHD), atrial fibrillation (AF), and stroke. Results. Women compared to men had higher NT-proBNT concentration was higher in women compared to men, in both genders it rose with age. Overall 17.9% of examinees had elevated NT-proBNT levels (14.2 and 20.3% among men and women, respectively). Elevated NT-proBNP level was associated in men with age, myocardial infarction, angina pectoris, ischemic ECG changes, left ventricular hypertrophy, AF, bradycardia, smoking, in women with age, IHD, ischemic ECG changes, AF, bradycardia, heart rate >80 bpm, BP >160/95 mm Hg. Conclusion. In studied RF population elevated NT-proBNP level was significantly associated with gender, age, smoking, and CVD.

мозговой натрийуретический пептид, сердечно-сосудистые заболевания, популяция РФ, brain natriuretic peptide, cardiovascular diseases, RF population

1. Potter L.R., Abbey-Hosch S., Dickey D.M. Endocrine Rev 2006; 27: 47-72.

2. Фомин И.В. Артериальная гипертония в Российской Федерации -последние 10 лет. Что дальше? Сердце 2007; 6 (3): 1-6.

3. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В. кн.: Хроническая сердечная недостаточность [Агеев Ф.Т. и соавт.] М.: ГЭОТАР-Медиа, 2010; c. 7-77.

4. Grewal J., McKelvie R., Lonn E. et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J. Heart Fail 2008; 10 (3): 252-259.

5. Di Angelantonio E., Chowdhury R., Sarwar N. et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120 (22): 2177-2187.

6. Vasan R.S., Benjamin E.J., Larson M.G. et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. The Framingham Heart Study. JAMA 2002; 288: 1252-1259.

7. Hobbs F.D.R., Davis R.C., Roalfe A.K. et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324: 1498-1500.

8. Loke I., Squire I.B., Davies J.E., Ng L.L. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J. Heart Fail 2003; 5: 599-606.

9. Welsh P., Doolin O., Willeit P. et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J. 2013; 34 (6): 443-450. doi: 10.1093/eurheartj/ehs239.

10. Борисов С.Н., Гендлин Г.Е. Применение натрийуретических пептидов в диагностике хронической сердечной недостаточности. Атмосфера. Новости кардиологии 2011; 2: 13-15.

11. Федотова И.Н., Белопольский А.А., Стуров Н.В. Диагностическая значимость NT-proBNP у кардиологических больных. Трудный пациент 2013; 11 (7): 32-35.

12. Тертичная С.П., Паршукова В.Н. Мозговой натрийуретический пептид в диагностике сердечной недостаточности у больных хронической обструктивной болезнью легких. Клиническая практика 2011; 4: 29-34.

13. Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина 2013; 6: 25-34

14. Galasko G.I., Lahiri A., Barnes S.C. et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005; 26 (21): 2269-2276.

15. Clark M., Kaufman V., Fulks M. et al. NT-proBNP as a predictor of all cause mortality in a population of insurance applicants. J. Insur Med 2014; 44 (1): 7-16.

16. Ponikowski P., Voors A.A., Anker S.D. et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129-2200.

17. Redfield M.M., Rodeheffer R.J., Jacobsen S.J. et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am Coll Cardiol 2002; 40: 976-982.

18. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность 2006; 7 (3): 112-115.

19. Otsuka T., Kawada T., Seino Y. et al. Relation of smoking status to serum levels of N-terminal pro-brain natriuretic peptide in middle-aged men without overt cardiovascular disease. Am J. Cardiol 2010; 106 (10): 1456-1460. doi: 10.1016/j.amjcard.2010.06.075

20. Nadruz W., Gonçalves, A., Claggett B. et al. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J. Heart Fail 2016; 18: 629-637. doi: 10.1002/ejhf.511

21. Khaled S.A., El-Amir A.M. Effect of exposure to second-hand smoke on serum levels of N-terminal pro-brain natriuretic peptide. Kasr Al Ainy Med J. 2015; 21: 22-26.

22. Jug B., Sebestjen M., Sabovic M. et al. Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure. Wien Klin Wochenschr 2009; 121 (21-22): 700-706. doi: 10.1007/s00508-009-1269-5.

23. Mishra R.K., Beatty A. L., Jaganath R. et al. B-type Natriuretic Peptides for the Prediction of Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study. J. Am Heart Assoc 2014; 3 (4): e000907.

24. Paget V., Legedz L., Gaudebout N. et al. N-Terminal ProBrain Natriuretic Peptide. A Powerful Predictor of Mortality in Hypertension. Hypertension 2011; 57: 702-709.

25. Leon D.A., Shkolnikova V.M., Borinskaya S.A. et al. Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies Eur J. Epidemiol 2013; 28: 393-404. DOI 10.1007/s10654-013-9808-9

26. Шальнова С.А., Деев А.Д., Капустина А.В., и др. Масса тела и ее вклад в смертность от сердечно-сосудистых заболеваний и всех причин среди российского населения. Кардиоваскул терап и проф 2014; 13 (1): 44-48.

27. Wang T.J., Larson M.G., Levy D. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.

28. Wang T.J., Larson M.G., Levy D. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl J. Med 2004; 350 (7): 655-663.